LT. GOVERNOR BROWN ADDRESSES MARYLAND’S LIFE SCIENCES COMMUNITY,
KICKS OFF PROGRAM ON TRAUMATIC BRAIN INJURY AT BIO INTERNATIONAL
CONVENTION IN CHICAGO
CHICAGO, Ill. (April 24, 2013) – Lt. Governor Anthony G. Brown today attended the 2013 BIO International Convention in Chicago, where he hosted a breakfast for members of Maryland’s life sciences community and also kicked off a day-long program on Maryland’s advancements in the diagnosis, treatment and prevention of Traumatic Brain Injury (TBI). As part of the breakfast meeting, several of Maryland’s life sciences companies shared updates on their progress, including Rockville-based Neuralstem, which announced today that it is working with the National Football League Alumni Association (NFLAA) to develop a drug trial for treating NFL alumni members suffering from traumatic brain injuries.
“Marylanders are at the forefront of innovation. The work that is being done at every level – from our local economic development partners and higher education institutions, to our federal research facilities and private companies – is changing the way we feed, fuel and heal our planet,” said Lt. Governor Brown. “I was particularly honored to talk about how Maryland is leading the way in addressing Traumatic Brain Injury. I am proud that within our borders we have so many smart people dedicated to unraveling the mysteries of the brain, which will ultimately mean a better quality of life not just for those Marylanders affected, but for millions around the globe.”
Maryland recently established the Maryland Brain Injury Trust Fund to help citizens with Traumatic Brain Injury pay for medical expenses. In addition, the National Institutes of Health (NIH), located in Maryland, will devote its top scientists to meeting the goals of President Barack Obama’s BRAIN (Brain Research through Advancing Innovative Neurotechnologies) initiative, which was launched earlier this month to better understand the human mind and uncover new ways to treat, prevent, and cure brain disorders like Alzheimer’s, schizophrenia, autism, epilepsy, and Traumatic Brain Injury. NIH was also recently awarded a $30 million donation from the National Football League for brain injury research.
During the breakfast meeting, the Lt. Governor also thanked outgoing BIO chairman Tom Watkins, chair of Maryland’s Life Sciences Advisory Board and former CEO of Human Genome Sciences, and congratulated Rachel King, co-founder and CEO of GlycoMimetics of Gaithersburg, who was appointed as BIO’s new chair. King formerly served as Vice Chair of BIO’s Health Section Governing Board, as well as on the Executive Committee, and is a former Chair of the Emerging Companies Section Governing Board.
“Rachel King brings a depth of industry experience and passion for advocacy that will serve BIO and its members well,” said Jim Greenwood, President and CEO of BIO. “I look forward to working closely with Rachel and our newly-constituted Board of Directors in the years to come.”
GlycoMimetics recently announced positive results in a phase II study of a drug designed to treat patients with sickle cell disease.
Under Maryland Governor Martin O’Malley and Lt. Governor Brown’s leadership, the State has made a number of strategic investments in Maryland’s life sciences industry. In 2007, the Governor created the Maryland Life Sciences Advisory Board, which developed a comprehensive, long-term plan to maximize Maryland’s unique research and development assets, and grow Maryland’s life sciences industry. As a result of the Board’s work, the Governor in 2009 launched BioMaryland 2020, a 10-year, $1.3 billion strategy for moving Maryland’s life sciences industry forward. Since 2010, roughly $600 million has been spent on BioMaryland initiatives, which is split evenly between funding for infrastructure and programs, including the State’s highly successful Biotechnology Tax Credit.